Kiromic BioPharma, Inc. KRBP
At closeApr 11, 2025, 4:00 PM EDT
52-week range unavailable
- Market cap
- 3.40M
- Shares out
- 1.18M
- Forward P/E
- -1.86
- Volume
- 42.93K
- Open
- 0.3031
- Previous close
- 0.081
- Day's range
- 0.081 – 0.3101
- Beta
- 0.15
Key statistics
- Enterprise value
- 12.92M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -11.26M
- Total cash
- 2.05M
- Total debt
- 11.97M
- Return on equity
- -549.34%
- Short % of float
- 4.42%
- 50-day average
- 3.46
- 200-day average
- 5.70
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 8, 2024 | Sep 1, 2024 | 0.00 | -0.65 | — | — |
| Aug 9, 2024 | Jun 1, 2024 | 0.00 | -0.74 | — | — |
| May 10, 2024 | Mar 1, 2024 | 0.00 | -1.00 | — | — |
| Mar 18, 2024 | Dec 1, 2023 | 0.00 | -4.16 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -1.52 | — | — |
| Aug 14, 2023 | Jun 1, 2023 | 0.00 | -1.54 | — | — |
About Kiromic BioPharma, Inc.
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- kiromic.com
News
Gainey McKenna & Egleston Announces the Proposed Class Action Settlement on Behalf of Purchasers of Kiromic BioPharma Inc. common stock - KRBPQ 
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival 
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01 
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation 
SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews 
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01 
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial 
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial 
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial 
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
Your note
Sign in to keep a note on KRBP — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BERSANI PIETRO | Chief Executive Officer | Stock Award(Grant) | Aug 10, 2022 | 638,298 |
| CHIRIVA INTERNATI MAURIZIO | Chief Executive Officer | Purchase | Sep 8, 2021 | 1,378,070 |
| CLARK DANIEL GRANT | Chief Financial Officer | Stock Award(Grant) | Aug 10, 2022 | 62,770 |
| DAHLBECK SCOTT | Officer | Stock Award(Grant) | Aug 10, 2022 | 496,757 |
| SCHNEIDER JERRY A | Director | Purchase | May 23, 2021 | 5,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Susquehanna International Group, LLP | 1.40% | 16,457 | 47.56K | Mar 30, 2023 |
| Tower Research Capital LLC (TRC) | 0.13% | 1,559 | 4.50K | Mar 30, 2023 |
| UBS Group AG | 0.10% | 1,222 | 3.53K | Mar 30, 2023 |
| Blackrock Inc. | 0.07% | 809 | 2.34K | Mar 30, 2023 |
| Morgan Stanley | 0.00% | 40 | 115 | Mar 30, 2023 |
| Group One Trading, L.P. | 0.00% | 8 | 23 | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.12% | 1,222 | 3.53K | Feb 27, 2023 |
| Fidelity Extended Market Index Fund | 0.01% | 143 | 413 | Feb 27, 2023 |